Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

MedaSystems Announces Major Platform Update to Help Life Sciences Organizations Govern and Scale Expanded Access Programs

in plain language, so quality teams, auditors and program leads can follow the record without interpretation. The same clarity applies at the organization level, where changes to users, access and configuration are captured alongside program...

Excedr Secures $25 Million in Growth Capital to Expand Its Life Sciences Equipment Leasing Platform

It brings the financial insight and resources you'd expect from a national institution — but delivers it with the care, clarity, and consistency of a neighbor who knows your name and understands your goals. Its Asset-Based Lending group specializes...

Nnamdi Njoku Named President of Omnicell

relationships with our customers and the investment community,” said Mr. Lipps. “Nnamdi is a proven leader who brings clarity, discipline, and precision to our efforts to scale our business and accelerate momentum for our strategy. This appointment...

Rugiet Launched Physician-Prescribed Peptide and Longevity Therapies, Setting a New Standard in Performance Medicine

NAD+: Restores cellular energy. NAD+ levels naturally decline with age — replenishing them supports stamina, mental clarity, and metabolic function. Glutathione: Supports cellular defense against stress, immune function, and recovery. Lipo-C: Helps...

FoundationOne® Diagnostics Approved for TALZENNA®–XTANDI® Therapy

Courtney Bugler, President and CEO of ZERO Prostate Cancer. “Biomarker testing gives patients and their families the clarity they need to understand their diagnosis and make informed decisions about care. Every person deserves access to...

Dr. Amit Singal Appointed as Chief Medical Officer by Curve Biosciences

the world’s largest collection of comprehensively-characterized tissue samples into its Whole-Body Atlas. Trained on the clarity of this atlas, the company’s Whole-Body Intelligence models identify chronic disease states through its Whole-Body...

FTC Warns PBM Practices Drive Higher Drug Costs as Employers Push Back

basis for discounts and rebates, and charges a transparent administrative fee. This structure offers operational clarity and fiscal alignment at a time of industry disruption. "The solution is already available," Luzzatti concluded. "It starts with...

SECuRE trial update: Another participant with negative PSMA PET and undetectable PSA

Clarity Pharmaceuticals a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that yet another participant with mCRPC in the...

First National Campaign Launched by Trauma Intervention Programs (TIP)

support to those impacted by trauma. At the heart of TIP's work are its volunteers, who are specially trained to offer clarity, comfort, and human connection during moments of crisis. "TIP's mission is to ensure no one has to face trauma alone,"...

Eisai Completes FDA Submission for LEQEMBI® IQLIK™ Subcutaneous Starting Dose.

subcutaneous (SC) administration of lecanemab across a range of doses and as part of sub-studies within the Phase 3 Clarity AD open-label extension (OLE) following the 18-month core study in individuals with early AD. Data show that once-weekly...

Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ Subcutaneous Maintenance Dose for Early Alzheimer's Treatment

in nine (9) countries and regions. LEQEMBI's approvals in these countries was based on Phase 3 data from Eisai's, global Clarity AD clinical trial, in which it met its primary endpoint and all key secondary endpoints with statistically significant...

Eisai submitted a rolling sBLA to the U.S. FDA for LEQEMBI® IQLIK™ as a subcutaneous starting dose to treat early Alzheimer’s, under Fast Track status

of subcutaneous (SC) lecanemab administration across a range of doses and as part of sub-studies within the Phase 3 Clarity AD open-label extension (OLE), following the 18-month core study in individuals with early AD. Should the FDA approve the...

To Redefine Specialty Care, Craft Telemedicine Launches with a Human-Centered Platform

transparent fee to receive their prescription and maintain complete freedom to fill it at any pharmacy of their choice. "Clarity is a form of care," said Arlee Riveland, CEO and Co-Founder. "I didn't set out to found a healthcare company, but I did...

Leqembi® approved in Mexico

Israel, the United Arab Emirates, and Great Britain. Leqembi's approval is based on data from the large global Phase 3 Clarity AD clinical trial, in which Leqembi met its primary endpoint and all key secondary endpoints with statistically...

Axonal.AI launches an industry-first platform to accelerate life sciences time to market

doesn't just incrementally improve the process – it fundamentally reimagines it. We are using AI to turn complexity into clarity and connect the dots between market insights, patient engagement, and compliance faster than ever before, enhancing the...

The U.S. FDA provides positive guidance on the Phase III trial of 64Cu-SAR-bisPSMA for recurrent prostate cancer.

Clarity Pharmaceuticals a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer. Is pleased to announce it will be commencing a pivotal...

Leqembi Secures Approval for Alzheimer's Disease Treatment in Hong Kong

following the US, Japan, China and South Korea. Leqembi's approval in Hong Kong is based on the large global Phase 3 Clarity AD study. In the Clarity AD study, Leqembi met its primary endpoint and all key secondary endpoints with statistically...

FDA Accepts sBLA Filing of Leqembi® (lecanemab-irmb) for IV Maintenance Dosing in Early Alzheimer's Treatment

based on modeling of observed data from the Phase 2 study (Study 201) and its open-label extension (OLE) as well as the Clarity AD study (Study 301) and its OLE study. Alzheimer's disease is a progressive disease caused by toxic amyloid proteins....

Editorial Guidelines | Pharmaceutical-Era.com

Avoid duplicate content and ensure all contributions are unique to Pharmaceutical-Era.com. 2. Structure and Formatting Clarity: Write clearly and concisely. Use straightforward language and avoid jargon unless it is industry-specific and...

Results 1 - 19 of 19